Activity Summary:
Conversations and Updates in Myelodysplastic Syndromes (MDS) is a roundtable discussion activity designed to inform and guide on the latest practice-changing insights to improve outcomes in both lower- and higher-risk MDS. The expert faculty presenters will discuss recent evidence and provide guidance on classifying, stratifying, and treating patients with MDS based on recent progress in the treatment continuum.

The activity is supported by downloadable slides that have the key discussion and teaching points.

Activity Summary:
Talking Hemophilia A is a roundtable discussion continuing education activity designed to inform and guide on integrating novel therapies into hemophilia A treatment paradigms.

The expert faculty presenters will provide an overview of existing approaches and their limitations and how new and emerging therapies can be used to address unmet needs. The activity will be supported by downloadable, supplemental slides that have the key discussion and teaching points.

Activity Summary:
Despite advances in the initial treatment strategies of multiple myeloma, many patients will experience an early relapse. The further management of such patients can be challenging given the various options and complex patient- and disease-related factors.

Conversations and Cases in Multiple Myeloma is a roundtable discussion activity designed to inform and guide on integrating recent progress in the management of early relapse. The expert faculty will discuss different cases with early relapse and provide guidance on safely using approved and emerging therapy to improve outcomes. The activity will be supported by downloadable slides that have key discussion and teaching points.

Activity Summary:
Lightning Reports are accredited, on-demand video presentations that feature experts discussing recent clinical updates, hot topics and treatment options. These activities are designed to keep healthcare professionals on top of the most recent clinical findings.

This series of accredited continuing education enduring videos will provide brief commentary spotlighting hot topics in myelodysplastic syndromes (MDS) presented at the 2022 American Society for Hematology (ASH) Annual Meeting from New Orleans, Louisiana.

Activity Summary:
Conversations and Updates in Gastric/GEJ Cancer is a roundtable discussion designed to inform and guide on the latest breakthroughs to improve patient outcomes.

Through patient cases and scenarios, the expert faculty presenters will illustrate the integration of new evidence and biomarkers to safely treat and manage diverse patients with gastric/GEJ cancer. The activity will be supported by downloadable slides that have the key discussion/teaching points.

Activity Summary:
The Talking Post-Transplant Acute Myeloid Leukemia (AML) webcast series will provide recent updates to improve outcomes in post-transplantation relapse in AML.

This webcast series, led by expert faculty, will provide guidance and practical strategies to safely implement recent progress in addressing post-transplantation relapse in AML. Through patient cases and scenarios, faculty presenters will guide the integration of new evidence into clinical treatment paradigms of AML in the post-transplantation setting. The activity will be supported by downloadable slides that have the key discussion/teaching points.

*Healthcare providers may only claim for the participation of one (1) enduring archive activity.

Activity Summary:
The Talking Multiple Myeloma webcast archive will highlight recent advances in the initial management of multiple myeloma (MM).

Through patient cases and scenarios, the expert faculty presenters will discuss practice-changing updates in the initial management of MM, strategies to improve patient outcomes and prevent/manage adverse events as well as guide the integration of new evidence into clinical treatment paradigms.

Activity Summary:
Combining tyrosine kinase inhibitor and immunotherapy agents has shown considerable promise in Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL). Although this approach can provide a chemotherapy-free and transplantation-sparing alternative, it is imperative that healthcare professionals are familiar with the practical considerations to safely integrate this recent progress.

This certified AMA activity will highlight the practice-changing updates in the frontline treatment of Ph+ ALL and provide guidance on effective implementation of new evidence through expert-guided discussions and interactive case scenarios.

Activity Summary:
Immune thrombocytopenic purpura (ITP) is a hematological autoimmune disorder characterized by low platelet count in the blood, which may lead to bruising and bleeding. For many years, immune-modulating therapies, such as corticosteroids, immunoglobulins (IVIG and anti-RhD), and rituximab, were the mainstays of treatment in ITP. Since 2008, the approval of thrombopoietin-receptor agonists (TPO-RAs) including a second-generation oral TPO-RA and a spleen tyrosine kinase (Syk) inhibitor, revolutionized the treatment landscape of ITP by opening new and highly effective avenues of treatment. This landscape will be further transformed with a sizable clinical pipeline including inhibitors of CD20, CD40, neonatal Fc receptor (FcRn), bruton’s tyrosine kinase (BTK), and Syk signaling.

This slide kit is designed to keep busy clinicians abreast of the emerging evidence for available treatments and the novel therapy pipeline, to optimize the treatment and care for patients with ITP.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Clinical Viewpoints HLH includes a curriculum that highlights the very latest clinical data in Hemophagocytic Lymphohistiocytosis (HLH). Slides are developed and updated throughout the year by leading HLH expert physicians. The Lecture Library offers various topics that can be accessed for AMA or ANCC credit. Review the content and complete the pre- and post-tests and evaluation to receive your credit.

HLH is an aggressive and life-threatening syndrome of excessive immune activation. In persons with HLH, timely diagnosis and appropriate treatment are essential to achieving a successful outcome. This activity will utilize case-based scenarios to review the diverse clinical presentations of suspected HLH, time-efficient approaches for diagnosis, and considerations for targeted treatment and supportive management strategies. Continue to visit the Lecture Library series throughout 2022 to view updates from new publications and conference updates. All content is reviewed and approved by the Clinical Viewpoints HLH Planning Committee.

Activity Summary:
The management of relapsed/refractory multiple myeloma (RRMM) is rapidly evolving due to continual updates from ongoing clinical trials on recently approved and emerging treatment approaches. Clinicians therefore need to stay abreast with recent progress to enable improved outcomes for patients.

This educational Clinical Clip will highlight important advances in RRMM based on data presented at the 63rd American Society of Hematology (ASH) Annual Meeting

Activity Summary:
The introduction of chimeric antigen receptor (CAR) T-cell therapies has shifted the paradigm for several incurable and refractory hematologic malignancies and currently various cellular immunotherapies are under investigation. To ensure updated ongoing care for patients, clinicians need to be familiar with recent clinical trial evidence on approved and emerging CAR T-cell therapies.

This educational Clinical Clip focused on CAR T-cell approaches has summarized key data presented at the 63rd American Society of Hematology (ASH) Annual Meeting.

Activity Summary:
Clinicians need to keep up with recent progress in low-risk myelodysplastic syndromes (MDS) to facilitate appropriate integration of newly approved and novel therapies

This educational Clinical Clip will highlight key updates in low-risk MDS based on data presented at the 63rd American Society of Hematology (ASH) Annual Meeting.

Activity Summary:
Clinical Clips are accredited, on-demand video presentations that feature experts discussing hot topics, recent clinical updates, conference updates and treatment options. These activities are designed to keep healthcare professionals on top of the most recent clinical findings in hematology/oncology.

This series will highlight key updates in low-risk myelodysplastic syndromes, relapsed/refractory multiple myeloma, and CAR T-cell therapy based on data presented at the 63rd American Society of Hematology (ASH) Annual Meeting.

Activity Summary:
Until recently, there has been a lack of treatment options for high-risk MDS. An increased understanding of the genetics and signaling pathways has led to the development of several novel agents and combinations for the treatment of high-risk MDS.

In this activity, Dr. Gail Roboz, Dr. Courtney DiNardo, and Dr. Rami Komrokji will deliberate on the most promising emerging therapies and their potential in improving outcomes for patients with high-risk MDS.

Activity Summary:
High-risk myelodysplastic syndromes (MDS) pose a challenge in terms of diagnosis, risk stratification, and treatment. Additionally, in recent years, the clinical, molecular, cellular, and immunological factors associated with high-risk MDS have become clearer.

This has led to several updates in the diagnosis and management of high-risk MDS, which will be discussed by Dr. Gail Roboz, Dr. Courtney DiNardo, and Dr. Rami Komrokji. The expert faculty will also review clinical case scenarios to guide participants in integrating recent updates in high-risk MDS.

Activity Summary:

These certified AMA/ANCC/ACPE activities feature a discussion among three experts that will review the current and emerging treatment landscape of high-risk myelodysplastic syndromes (MDS). The program includes two activities that will feature the faculty discussing recent updates in the standard of care for high-risk MDS and what is on the horizon for high-risk MDS.

Activity Summary:
Effective strategies for immune thrombocytopenia (ITP) continue to evolve and clinicians are often challenged when presented with clinical scenarios not adequately addressed by current treatment guidelines. Many times treatment decisions necessitate consideration of the most recent clinical trial data.

These educational Clinical Clips will highlight important advances in the medical management of patients with ITP based on data presented at the 2021 International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress.

Activity Summary:
These certified CME interactive case presentations will review recent clinical trial and published data that will support the appropriate management and treatment decisions recommended by the expert faculty in multiple myeloma.

During these interactive case presentations Dr. Joseph Mikhael and Dr. Nina Shah will address scenarios focusing on a newly diagnosed patient, early relapse, late relapse and patient requiring maintenance therapy, will be presented and discussed. The activity will be supported by downloadable slides that have the key discussion/teaching points.

Activity Summary:
Effective strategies for immune thrombocytopenia (ITP) continue to evolve and clinicians are often challenged when presented with clinical scenarios not adequately addressed by current treatment guidelines. Many times treatment decisions necessitate consideration of the most recent clinical trial data.

These educational Clinical Clips will highlight important advances in the medical management of patients with ITP based on data presented at the 2021 European Hematology Association (EHA) Virtual Congress.

Activity Summary:

This certified CME/CNE activity features a recorded discussion among three experts that reviews the latest research and options for the management of patients with MPNs.

This activity will feature Dr. Srdan Verstovsek, Dr. Ruben Mesa and Dr. John Mascarenhas discussing the standard of care for Polycythemia Vera and Myelofibrosis. The discussion will be supplemented by slides based on key discussion points which are available for download.

Activity Summary:

These certified CME/CNE interactive case presentations will review the latest management strategies and treatment options for the management of acute leukemia.

During these interactive case studies Dr. Richard M. Stone will address the most clinically relevant data on Acute Lymphoblastic Leukemia and Dr. Farhad Ravandi address the most clinically relevant data on Acute Myeloid Leukemia. Each Interactive Case has thought-provoking questions from the faculty built into them giving users the opportunity to test their understanding of the material presented.

Activity Summary:
Effective strategies for immune thrombocytopenia (ITP) continue to evolve and clinicians are often challenged when presented with clinical scenarios not adequately addressed by current treatment guidelines. Many times treatment decisions necessitate consideration of the most recent clinical trial data.

These educational Clinical Clips will highlight important advances in the medical management of patients with ITP based on data presented at the 62nd American Society of Hematology (ASH) Annual Meeting through a series of two ‘what you need to know in 5-minutes’ videos.

Activity Summary:
Treatment choices for chronic immune thrombocytopenia (ITP) are complicated by the heterogeneity of the disease and the inability not only to diagnose it but also to objectively predict patient responses to treatment and outcomes. With lack of head-to-head clinical trial comparisons to guide therapeutic options and sequencing of treatment strategies, as well as the development of emerging agents, expert opinion is critical in guiding clinical decision-making. Furthermore, ITP in the elderly and pregnant patient poses considerable challenges, so specific individualized management strategies ideally should be considered to optimize outcomes.

Using patient case studies, James Bussel, MD and Hanny Al-Samkari, MD discuss real-life management of patients with chronic ITP.

Activity Summary:
Treatment paradigms for multiple myeloma have changed substantially over the last years with many advances in novel therapeutic approaches.

Presented by Dr. Joseph Mikhael of the Translational Genomics Research Institute, City of Hope Cancer Center, and Chief Medical Officer of the International Myeloma Foundation, the archived recording of the certified-CME/CNE 1-hour live webcast will cover recent updates in the standard of care and review the latest approved products and new research for the management of multiple myeloma.

Activity Summary:
Chronic immune thrombocytopenia (ITP) is one of the most common causes of thrombocytopenia in adults. Diagnosis of ITP remains one of exclusion, and differential diagnosis with secondary forms is crucial to exclude other forms of thrombocytopenia, which may require a different therapeutic approach. Furthermore, chronic symptomatic ITP necessitates second-line treatments based on highly individualized considerations. Advances in the understanding of the pathogenesis have led to novel therapeutic targets, such as the thrombopoietin receptor agonists to aid in this personalized approach.

These educational Mini Modules will outline recent data on current and emerging treatment options for chronic ITP, including FcRn and spleen tyrosine kinase inhibitors.

Updated information is noted on the slide in the upper right hand corner. Please note that participants who have previously claimed credit for this activity should not claim duplicate credit based on the updates.

Activity Summary:
Thrombocytopenia is a common manifestation among patients with chronic liver disease. In the setting of advanced liver disease, thrombocytopenia may negatively impact patient care by interfering with diagnostic and therapeutic procedures. The development of thrombopoietin agonists has the potential to provide clinicians with new options to improve patient care. However, current guidelines provide limited guidance on the optimal approach to increase platelet counts in patients with chronic liver disease.

These educational Mini Modules will outline the pathophysiologic mechanisms, platelet threshold levels, and other factors that impact the decision to initiate treatment for thrombocytopenia. In addition, the benefits and limitations of current and emerging therapeutic options will be discussed.

Activity Summary:
Advances in cancer research unfold rapidly. In order to deliver state-of-the-art care, healthcare providers who manage this patient population must stay abreast of data emerging from the major conferences.

These educational Mini Modules will review data on castration resistant prostate cancer (CRPC) presented at the 2015 ASCO. Clinical trial data gives new insight into the timing and scheduling of currently approved agents for CRPC. In addition, investigational approaches to CRCP will be presented, as well as information relating to biomarkers and other methods of guiding day-to-day clinical decision-making in this tough-to-treat population.